Epirubicin Hydrochloride
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antineoplastic |
| Catalog number | BBF-04657 |
| CAS | 56390-09-1 |
| Molecular Weight | 579.98 |
| Molecular Formula | C27H29NO11.HCl |
| Purity | >98% |
Ordering Information
| Catalog Number | Size | Price | Stock | Quantity |
|---|---|---|---|---|
| BBF-04657 | 500 mg | $269 | In stock |
Online Inquiry
Add to cartDescription
Epirubicin HCl, a semisynthetic L-arabino derivative of doxorubicin, is an antineoplastic agent by inhibiting Topoisomerase.
Specification
| Related CAS | 56420-45-2 (free base) |
| Synonyms | epi-Doxorubicin HCl; (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,12-naphthacenedione Hydrochloride; (8S-cis)-4'-Epidoxorubicin Hydrochloride; 4'-epi-Adriamycin Hydrochloride; Ellence; Epidoxorubicin Hydrochloride; Farmorubicin; Pharmorubicin; NSC-759195; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- |
| Storage | Store at -20°C under inert atmosphere |
| IUPAC Name | (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride |
| Canonical SMILES | CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O.Cl |
| InChI | InChI=1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10-,13-,15-,17-,22-,27-;/m0./s1 |
| InChI Key | MWWSFMDVAYGXBV-FGBSZODSSA-N |
Properties
| Appearance | Orange to Red Solid |
| Application | Antibiotics, Antineoplastic |
| Antibiotic Activity Spectrum | neoplastics (Tumor) |
| Melting Point | >150°C (dec.) |
| Solubility | Soluble in Methanol (Slightly, Heated), Water (Slightly) |
Reference Reading
1.Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T1, Järvinen R2, Liukkonen T3, Rintala E2, Boström P4, Seppänen M5, Tammela T6, Hellström P7, Aaltomaa S8, Leskinen M9, Raitanen M9, Kaasinen E10; FinnBladder Group. Eur Urol. 2016 Apr 13. pii: S0302-2838(16)30010-0. doi: 10.1016/j.eururo.2016.03.034. [Epub ahead of print]
BACKGROUND: Patients with non-muscle-invasive bladder cancer (NMIBC) belonging to the intermediate-risk group should be treated with intravesical instillations to prevent recurrence and progression.
2.Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
Tsuda T1, Kyomori C2, Mizukami T1, Taniyama T1, Izawa N1, Horie Y1, Hirakawa M1, Ogura T1, Nakajima TE1, Tsugawa K3, Boku N1. Mol Clin Oncol. 2016 Apr;4(4):603-606. Epub 2016 Feb 5.
The incidences of infusion site adverse events in chemotherapy regimens, including anthracyclines with either fosaprepitant or aprepitant as the anti-emetic, were not highlighted in the randomized trial comparing aprepitant and fosaprepitant. The present retrospective analysis was performed in breast cancer patients receiving anthracycline-containing chemotherapy, a combination of epirubicin and cyclophosphamide with or without 5-fluorouracil as the adjuvant or neoadjuvant, at the outpatient infusion center of St. Marianna University Hospital (Kawasaki, Japan). Infusion site adverse events were retrospectively compared between the 3 months prior to and three months following switching from 3 day oral administration of aprepitant to intravenous infusion of fosaprepitant. A total of 62 patients were included in the aprepitant group and 38 in the fosaprepitant group. Of these patients, 26 (42%) in the aprepitant group and 36 patients (96%) in the fosaprepitant group experienced any grade of infusion site adverse events at least once (P<0.
3.Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
Xue K1,2, Gu JJ3, Zhang Q1,2, Liu X1,2, Wang J1,2, Li XQ4,2, Luo J5,2, Hernandez-Ilizaliturri FJ3, Fernandez SF6, Czuczman MS3, Cao J1,2, Hong X1,2, Guo Y1,2. Oncotarget. 2016 Apr 11. doi: 10.18632/oncotarget.8685. [Epub ahead of print]
Anthracycline-induced cardiotoxicity influences treatment selection and may negatively affect clinical outcomes in lymphoma patients. While epirubicin induced cardiotoxicity less often than the same dose of doxorubicin in breast cancer, higher doses of epirubicin are required in lymphoma regimens for equivalent efficacy. Whether a higher dosage of epirubicin also induces cardiotoxicity less often than doxorubicin in lymphoma remains unknown. We therefore administered 6-8 cycles of cyclophosphamide, vincristine and prednisone (CEpOP) +/- rituximab (R) with either epirubicin (CEpOP) or doxorubicin (CHOP) to patients (N=398) with untreated diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma grade 3 (FLG3). Left ventricular ejection fraction (LVEF) and high-sensitivity serum cardiac troponin T (HsTnT) were assessed at baseline and after 4 cycles of treatment. Epirubicin (70 mg/m2/dose) was equivalent to doxorubicin (50 mg/m2/dose) in terms of 3-year progression-free survival.
4.Epirubicin dose and sequential hormonal therapy-Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer.
Coombes RC1, Kilburn LS2, Tubiana-Mathieu N3, Olmos T4, Van Bochove A5, Perez-Lopez FR6, Palmieri C7, Stebbing J8, Bliss JM2. Eur J Cancer. 2016 Apr 25;60:146-153. doi: 10.1016/j.ejca.2016.03.001. [Epub ahead of print]
BACKGROUND: The hormonal manipulation 5-Fluoro-uracil Epirubicin Cyclophosphamide (HMFEC) trial was developed at a time of uncertainty around the dose intensity of chemotherapy given to premenopausal patients with node positive breast cancer and to the benefits of tailored endocrine therapy in such patients.
Recommended Products
| BBF-01829 | Deoxynojirimycin | Inquiry |
| BBF-03791 | Daptomycin | Inquiry |
| BBF-03796 | Bambermycin | Inquiry |
| BBF-00852 | Epothilon B | Inquiry |
| BBF-05727 | Tacrolimus monohydrate | Inquiry |
| BBF-03819 | Spinosyn A | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
